HSPC

(redirected from Hormone-Sensitive Prostate Cancer)
AcronymDefinition
HSPCHormone-Sensitive Prostate Cancer
HSPCHealth Science Planning Consultants (Australia)
HSPCHigh School Preparation Course (various universities)
HSPCHigh School Policy Center
HSPCHuman Services Planning Council
HSPCHigh Speed Passenger Craft (ship)
HSPCHeat Sterilizable Potting Compound
References in periodicals archive ?
'We are pleased to receive the Priority Review designation, which reflects the need for more treatment options for men living with metastatic hormone-sensitive prostate cancer,' said Chris Boshoff, M.D., Ph.D., Chief Development Officer, Oncology, Pfizer Global Product Development.
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
ADT: androgen-deprivation therapy; CRPC: castration-resistant prostate cancer; D: docetaxel; HSPC: hormone-sensitive prostate cancer; OS: overall survival.
In addition to the Phase III trial ARAMIS in men with nmCRPC, darolutamide is also being investigated in a Phase III study in metastatic hormone-sensitive prostate cancer (ARASENS).
Pfizer and Astellas Pharma announced today results from the Phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer. Prostate cancer is considered metastatic once the cancer has spread outside of the prostate gland to other parts of the body.
M2 PHARMA-June 3, 2019-Erleada Significantly Improved Overall Survival and Radiographic Progression-Free Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Astellas Pharma (ALPMY) and Pfizer (PFE) announced that the Phase 3 ARCHES trial evaluating XTANDI plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer met its primary endpoint, significantly improving radiographic progression-free survival versus ADT alone.
With the amendments to ARCHES and EMBARK, we will be able to evaluate the potential of XTANDI for men with hormone-sensitive prostate cancer sooner, including for those with non-metastatic disease in which there are no currently approved oral treatment options.'
There have been studies that suggest hormone-sensitive prostate cancer with oligometastasis may well be eligible for a similar approach given the remarkably favourable prognosis observed in men with oligometastasis.